British Journal of Clinical Pharmacology · 2010 · 79 citations · 28 references
MedicinePharmacokineticsPharmacologyBiochemical PharmacologyDrug MetabolismMetabolismCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesHepatic Drug MetabolismHepatic MetabolismMetabolite IdentificationConjugationCytochrome P450 3A4 MetabolismCytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 Human Liver MicrosomesCytochrome P450 Metabolic PathwaysEnzymesMicrosomal Drug Metabolism
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Anastrozole is primarily cleared by hepatic metabolism via oxidative and conjugating enzymes. WHAT THIS STUDY ADDS • Anastrozole is oxidized to hydroxyanastrozole mainly by CYP3A4/5 and glucuronidated to anastrozole glucuronide predominantly by UGT1A4 in vitro . • Hydroxyanastrozole glucuronide and hydroxyanastrozole were quantified as the major metabolites of anastrozole in plasma of breast cancer patients. • This study describes for the first time anastrozole metabolic pathways and the enzymes involved, which may serve as the scientific basis for pharmacogenetic and drug‐interaction assessments. AIMS Little information is available regarding the metabolic routes of anastrozole and the specific enzymes involved. We characterized anastrozole oxidative and conjugation metabolism in vitro and in vivo . METHODS A sensitive LC‐MS/MS method was developed to measure anastrozole and its metabolites in vitro and in vivo . Anastrozole metabolism was characterized using human liver microsomes (HLMs), expressed cytochrome P450s (CYPs) and UDP‐glucuronosyltransferases (UGTs). RESULTS Hydroxyanastrozole and anastrozole glucuronide were identified as the main oxidative and conjugated metabolites of anastrozole in vitro , respectively. Formation of hydroxyanastrozole from anastrozole was markedly inhibited by CYP3A selective chemical inhibitors (by >90%) and significantly correlated with CYP3A activity in a panel of HLMs ( r = 0.96, P = 0.0005) and mainly catalyzed by expressed CYP3A4 and CYP3A5. The K m values obtained from HLMs were also close to those from CYP3A4 and CYP3A5. Formation of anastrozole glucuronide in a bank of HLMs was correlated strongly with imipramine N ‐glucuronide, a marker of UGT1A4 ( r = 0.72, P < 0.0001), while expressed UGT1A4 catalyzed its formation at the highest rate. Hydroxyanastrozole (mainly as a glucuronide) and anastrozole were quantified in plasma of breast cancer patients taking anastrozole (1 mg day −1 ); anastrozole glucuronide was less apparent. CONCLUSION Anastrozole is oxidized to hydroxyanastrozole mainly by CYP3A4 (and to some extent by CYP3A5 and CYP2C8). Once formed, this metabolite undergoes glucuronidation. Variable activity of CYP3A4 (and probably UGT1A4), possibly due to genetic polymorphisms and drug interactions, may alter anastrozole disposition and its effects in vivo .
28
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text